Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 6
1984 8
1985 7
1986 11
1987 22
1988 29
1989 20
1990 34
1991 26
1992 17
1993 27
1994 28
1995 16
1996 25
1997 27
1998 21
1999 25
2000 36
2001 33
2002 40
2003 23
2004 22
2005 32
2006 23
2007 33
2008 33
2009 34
2010 28
2011 25
2012 33
2013 38
2014 22
2015 24
2016 17
2017 16
2018 21
2019 15
2020 12
2021 11
2022 12
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Shim M, et al. Investig Clin Urol. 2019 Jul;60(4):244-250. doi: 10.4111/icu.2019.60.4.244. Epub 2019 May 21. Investig Clin Urol. 2019. PMID: 31294133 Free PMC article.
PURPOSE: To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) with goserelin, triptorelin, and leuprolide. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 125 patients with …
PURPOSE: To investigate the changes in testosterone levels and rates of chemical castration following androgen-deprivation therapy (ADT) wit …
Goserelin acetate in combination with radiotherapy for prostate cancer.
Roach M 3rd, Izaguirre A. Roach M 3rd, et al. Expert Opin Pharmacother. 2007 Feb;8(2):257-64. doi: 10.1517/14656566.8.2.257. Expert Opin Pharmacother. 2007. PMID: 17257094 Review.
Improvements in longer-term survival rates have been demonstrated for locally advanced prostate cancer patients treated with adjuvant androgen deprivation therapy (ADT), and in subsets of men with clinically localized disease treated with ADT combined with external- …
Improvements in longer-term survival rates have been demonstrated for locally advanced prostate cancer patients treated with a …
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, Liang C, Liu H, Yu Y, Xu Z, Liu S, Wang J, Jia L, Yao X, Liao W, Fu C, Tan Z, He G, Zhu G, Fan R, Yang W, Chen X, Liu Z, Zhong L, Shi B, Ding D, Chen S, Wei J, Yao X, Chen M, Lu Z, Xie Q, Hu Z, Wang Y, Guo H, Fan T, Liang Z, Chen P, Wang W, Xu T, Li C, Xing J, Liao H, He D, Wu Z, Yu J, Feng Z, Yang M, Dou Q, Zeng Q, Li Y, Gou X, Zhou G, Wang X, Zhu R, Zhang Z, Zhang B, Tan W, Qu X, Sun H, Gan T, Ye D. Gu C, et al. Chin Med J (Engl). 2023 May 20;136(10):1207-1215. doi: 10.1097/CM9.0000000000002638. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010251 Free PMC article. Clinical Trial.
This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients wit …
This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. MET …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Brogden RN, Faulds D. Brogden RN, et al. Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007. Drugs Aging. 1995. PMID: 7613021 Review.
In men with untreated advanced prostate cancer, monthly goserelin 3.6mg has been confirmed as similar in efficacy to surgical castration and diethylstilbestrol (stilboestrol) 3mg daily taken orally. ...Surgical castration remains the treatment of choice in pa …
In men with untreated advanced prostate cancer, monthly goserelin 3.6mg has been confirmed as similar in efficacy to su …
Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y, Zong H, Yan H, Li N, Zhang Y. Cui Y, et al. Urol Int. 2014;93(2):152-9. doi: 10.1159/000356272. Epub 2014 Mar 1. Urol Int. 2014. PMID: 24603064 Review.
OBJECTIVE: We performed a systematic review and meta-analysis to assess the efficacy and tolerability of degarelix for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer (PCa). ...RESULTS: …
OBJECTIVE: We performed a systematic review and meta-analysis to assess the efficacy and tolerability of degarelix for lower urinary tract s …
Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
Raja T, Sud R, Addla S, Sarkar KK, Sridhar PS, Talreja V, Jain M, Patil K. Raja T, et al. Indian J Cancer. 2022 Mar;59(Supplement):S142-S159. doi: 10.4103/ijc.IJC_65_21. Indian J Cancer. 2022. PMID: 35343198 Free article. Review.
Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review, we assessed the efficacy, safety, and convenience of administration of various GnRH-A. ...Lack of …
Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist (s) (GnRH-A) remains the backbone of advanced prostate …
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
Chen N, Wang Z, Chen M, Ma Q, He Y, Wang Y, Li X, Qiu M, Shi L, Zhu S, Xie Q, Liu X, Shi B, Lin G, Yang W, Liao Y, Zhang H, Wang S, Li J, Wang S, Dong L, Chen H, Lu J, Cheng Y, Zhang X, Ma L, Zhou L, Wang H, Li S, Ye D. Chen N, et al. Cancer Biol Med. 2024 Feb 5;20(12):1047-59. doi: 10.20892/j.issn.2095-3941.2023.0335. Cancer Biol Med. 2024. PMID: 38318809 Free PMC article.
OBJECTIVE: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate cancer are limited. This study aimed to determine the real-world effectiveness and safety of the LHRH agonist, goserelin, particul …
OBJECTIVE: Real-word data on long-acting luteinizing hormone-releasing hormone (LHRH) agonists in Chinese patients with prostate c …
Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.
Akaza H. Akaza H. BJU Int. 2004 Jan;93(1):42-6. doi: 10.1111/j.1464-410x.2004.04552.x. BJU Int. 2004. PMID: 14678365 Review.
This article reviews the clinical disease-free survival (DFS) and disease-related mortality (DRM) data from published prospective, randomized trials of goserelin, given alone as adjuvant treatment or combined with a nonsteroidal antiandrogen as neoadjuvant treatment in pat …
This article reviews the clinical disease-free survival (DFS) and disease-related mortality (DRM) data from published prospective, randomize …
Development of GnRH antagonists for prostate cancer: new approaches to treatment.
Cook T, Sheridan WP. Cook T, et al. Oncologist. 2000;5(2):162-8. doi: 10.1634/theoncologist.5-2-162. Oncologist. 2000. PMID: 10794807 Free article. Review.
Prostate cancer has become the most common cancer among American men and is second only to lung cancer as a cause of male cancer-related death. ...Abarelix, a peptide antagonist of GnRH receptor, is also being studied for the treatment of pro …
Prostate cancer has become the most common cancer among American men and is second only to lung cancer as a caus …
Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V. Mason M, et al. Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6. doi: 10.1016/j.clon.2012.09.010. Epub 2012 Dec 17. Clin Oncol (R Coll Radiol). 2013. PMID: 23257248 Clinical Trial.
AIMS: The treatment of intermediate- to high-risk prostate cancer with radical radiotherapy is usually in combination with neoadjuvant androgen deprivation therapy. ...MATERIALS AND METHODS: The study was a randomised, parallel-arm, active-controlled, open-label tri …
AIMS: The treatment of intermediate- to high-risk prostate cancer with radical radiotherapy is usually in combination with neo …
889 results